Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal International Journal of Public Health Science (IJPHS) Indonesian Journal of Cancer
Putra, Probo Yudha Pratama
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Irritable bowel syndrome following infectious COVID-19: East Java, Indonesia, 2023 Hanum, Aisyah Rizki Nirmala; Illahika, Anung Putri; Santoso, Aktaruddin Arief; Putra, Probo Yudha Pratama
International Journal of Public Health Science (IJPHS) Vol 13, No 2: June 2024
Publisher : Intelektual Pustaka Media Utama

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11591/ijphs.v13i2.23547

Abstract

Irritable bowel syndrome (IBS) is a functional disorder that causes chronic abdominal pain without a known cause. It is a common, chronic gastrointestinal (GI) motility disorder with bothersome symptoms that often lower quality of life and activity. In addition, Patients and healthcare facilities also face significant financial costs. COVID-19 directly damages the digestive system and alters the complex interaction of physical, mental, and social factors that cause digestive problems. SARS-CoV-2 survivors in personal isolation will be examined for IBS prevalence. The dates of this descriptive cross-sectional study are January through April 2023. Rome IV criteria and an online questionnaire were used to confirm the diagnosis of IBS. The principal location where polls have been sent is East Java, Indonesia. The 96 COVID-19 survivors aged 18–60 of both genders was included during self-quarantine. There were 59 females (61.46%) and 37 males (38.54%). The prevalence of IBS was discovered to be 19 (19.79%) among a total of 96 patients. This could be because self-quarantined people have more stable living conditions than hospitalized people. Based on these findings, it is suggested that future research consider gender as the primary proxy for identifying irritable bowel syndrome (IBS).
The Impact of Antitumor Treatment on Cancer Patients with COVID-19: A Systematic Review and Meta-Analysis Ananto, Farizky Jati; Purwanto, Heru; Ayuda, Caesar; Wibiseno, Dono Marsetio; Putra, Probo Yudha Pratama; Wardhana, Burhan Mahendra Kusuma; Putra, Doddy Setya Adi
Indonesian Journal of Cancer Vol 18, No 3 (2024): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i3.1158

Abstract

Background: Cancer is a chronic disease that can cause various complications, decrease the immune system, reduce quality of life, and even lead to death. In addition, the COVID-19 pandemic in various countries has had a significant adverse impact on patients. This study analyzed the impact of various antitumor treatments on cancer patients with COVID-19. Methods: This meta-analysis was conducted according to the PRISMA – P pathway. Source searches were conducted in PubMed, Cochrane Library, Research Gate, and Science Direct in cancer patients with COVID-19 receiving various types of antitumor treatment. Analysis was performed using RevMan V.5.3 software with the outcome of mortality rate and severe COVID-19. Results: Twenty-five observational studies met the inclusion criteria with a total of 21,940 patients. There was no significant difference in mortality rate (OR 1.08, 95% CI 0.99 – 1.18, p = 0.09), but there was a significant difference in severe COVID-19 (OR 1.19, 95% CI 1.02 – 1.39, p = 0.02). Immunotherapy provided the most significant worsening of both mortality rate (OR 1.39, 95% CI 1.17 – 1.64, p = 0.0001) and severe COVID-19 (OR 1.82, 95% CI 1.23 – 2.71, p = 0.003). There were no significant differences in other antitumor treatments. Conclusions: Antitumor treatment does not have a significant impact on mortality rate, but has a significant impact on worsening the degree of COVID-19. Among all the antitumor therapies that provide the highest potential for worsening is immunotherapy.
Co-Authors Anung Putri Illahika Ayuda, Caesar Farizky Jati Ananto, Farizky Jati Hanum, Aisyah Rizki Nirmala Heru Purwanto Putra, Doddy Setya Adi Santoso, Aktaruddin Arief Wardhana, Burhan Mahendra Kusuma Wibiseno, Dono Marsetio